Exemestane for breast cancer prevention: A feasible strategy?

Clinical Cancer Research

Volumn 11, Issue 2 II, 2005, Pages

  Lønning, Per E ^a   Buzdar, Aman ^b   Santen, Richard ^b   Johnston, Stephen ^b   Arteaga, Carlos ^b   Yee, Douglas ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; APOLIPOPROTEIN A1; AROMATASE INHIBITOR; CELECOXIB; ESTROGEN; EXEMESTANE; FORMESTANE; HIGH DENSITY LIPOPROTEIN; LETROZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TAMOXIFEN;

ANIMAL MODEL; BONE METABOLISM; BREAST CANCER; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME INHIBITION; ESTROGEN THERAPY; FEMALE; FRACTURE; GENE MUTATION; HIGH RISK POPULATION; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MENOPAUSAL SYNDROME; MUSCULOSKELETAL DISEASE; NONHUMAN; ONCOGENE; PAIN; POSTMENOPAUSE; PRIORITY JOURNAL; RAT;

ANDROSTADIENES; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; POSTMENOPAUSE; RISK FACTORS;

EID: 12144274735     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (65)

1. Early Breast Cancer Trialist Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
2. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000.
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90: 1371-88.
4. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998;352:93-7.
5. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
6. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet 2002;360:817-24.
7. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
8. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 1999;281:2189-97.
9. Bonneterre J, Buzdar A, Nabholtz J-M, et al. Anastrozole is superior to Tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-58.
10. Mouridsen H, Gershanovick M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol 2003; 21:2101-9.
11. Paridaens R, Therasse P, Dirix L, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - a randomized phase III trial of the EORTC Breast Group [abstract 515]. Am Soc Clin Oncol 2004;2004:6.
12. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
13. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
14. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350: 1081-92.
15. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-7.
16. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996; 88:291-6.
17. Thomas HV, Key TJ, Allen DS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Br J Cancer 1997;76:401-5.
18. Dorgan JF, Longcope C, Stephenson HE, et al. Serum sex hormone levels are related to breast cancer risk in postmenopausal women. Environ Health Perspect 1997;105:583-5.
19. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-9.
20. Garland CF, Friedllander NJ, Khaw KT. Sex hormones and postmenopausal breast cancer: a prospective study in an adult community. Am J Epidemiol 1992;135:1220-30.
21. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med 1999; 130:270-7.
22. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 2000;9:575-9.
23. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994;18:79-85.
24. MacNeill FA, Jones AL, Jacobs S, Lønning PE, Powles TJ, Dowsett M. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 1992;66:692-7.
25. MacNeill FA, Jacobs S, Lønning PE, Powles TJ, Dowsett M. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression. Br J Cancer 1994;69:1171-5.
26. MacNeill FA, Jacobs S, Dowsett M, Lønning PE, Powles TJ. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients. Cancer Chemother Pharmacol 1995;36:249-54.
27. Lønning PE, Jacobs S, Jones A, Haynes B, Powles T, Dowsett M. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer 1991;63:789-93.
28. Jones AL, MacNeill F, Jacobs S, Lønning PE, Dowsett M, Powles TJ. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 1992; 28A:1712-6.
29. Lønning PE. Aromatase inhibitors and inactivators for breast cancer therapy. Drugs Aging 2002;19:277-98.
30. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089-93.
31. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex®), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74:1286-91.
32. Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE. Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study. J Clin Oncol 2002;20:751-7.
33. Miller WR, Dixon JM. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer 2000;1:s9-14.
34. Johannessen DC, Engan T, Salle Ed, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997;3:1101-8.
35. Murray R, Pitt P. Aromatase inhibition with 4-OH androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 1995;35:249-53.
36. Geisler J, Johannessen DC, Anker G, Lønning PE. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: clinical and endocrine effects. Eur J Cancer 1996;32A:789-92.
37. HarperWynne C, Coombes RC. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. Eur J Cancer 1999;35:744-6.
38. Thürlimann B, Paridaens R, Serin D, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Eur J Cancer 1997;33:1767-73.
39. Carlini P, Frassoldati A, DeMarco S, et al. Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? Ann Oncol 2001;12:1539-43.
40. Trichopoulos D, MacMahan B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605-13.
41. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian national breast screening study. J Natl Cancer Inst 1995; 87:670-5.
42. Zhang YQ, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 1997; 336:611-7.
43. Recht A, Silen W, Schnitt SJ, et al. Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. Int J Radiat Oncol Biol Phys 1988;15:255-61.
44. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347:567-75.
45. Liehr J. Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 1997;6:3-10.
46. Liehr JG. 4-Hydroxylation of oestrogens as a marker for mammary tumours. Biochem Soc Trans 1999;27:318-23.
47. Frost VJ, Helle SI, Lønning PE, Stappen JWJvd, Holly JMP. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J Clin Endocrinol Metab 1996;81:2216-21.
48. ATAC. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer-results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10.
49. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
50. Goss PE, Qi S, Josse RG, et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004;34: 384-92.
51. Lønning PE, Geisler J, Krag L, et al. Effect of exemestane on bone: a randomized placebo controlled study in postmenopausal women with early breast cancer at low risk. Am Soc Clin Oncol 2004;23:6.
52. Geisler J, Lønning PE, Krag L, et al. Estrogens and bone metabolism in postmenopausal women with early breast cancer at low risk treated with exemestane: a randomized placebo-controlled study. Am Soc Clin Oncol 2004;23:9.
53. Krag L, Geisler J, Lønning PE, et al. Lipid and coagulation profile in postmenopausal women with early breast cancer at low risk treated with exemestane: a randomized, placebo-controlled study. Am Soc Clin Oncol 2004;23:39.
54. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry- scientific review. JAMA 2002;288:1889-97.
55. Subar M, Goss P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors (Als) on markers of bone turnover and lipid metabolism in healthy volunteers. Am Soc Clin Oncol 2004; 23:734.
56. Raisz LG, Wiita B, Artis A, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1996;81:37-43.
57. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs high-density lipoprotein intervention trial. Am J Cardiol 2000;86:19L-220.
58. Gotto AM. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 2002;144:533-42.
59. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-12.
60. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Dir Assoc 1998;280:605-13.
61. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9.
62. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535-45.
63. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.
64. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. J Am Med Dir Assoc 2002; 288:2015-23.
65. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218-26.